Laevolac (Lactulose, Liquid)

Lactulose reaches the colon unchanged, where bacterial enzymes break it down into short‑chain acids. This acidifies the colonic environment, creating an osmotic pull that retains water in the lumen, softening stool, and converts ammonia to ammonium, which is less readily absorbed, thereby lowering blood ammonia levels.

The dose of Laevolac is individualized by the prescribing clinician based on the patient’s condition, age, and response. Typically, treatment starts with a low volume and is adjusted until the desired stool consistency or ammonia reduction is achieved.

Lactulose is classified as a pregnancy category that requires careful risk‑benefit assessment. It may be used during pregnancy or lactation only when clearly needed and prescribed by a qualified health professional.

To request Laevolac, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with polyethylene glycol‑based laxatives, lactulose also lowers colonic ammonia, offering a dual benefit for patients with liver disease. Polyethylene glycol primarily acts as an osmotic agent without affecting ammonia metabolism, making lactulose the preferred choice when hepatic encephalopathy risk is present.

Store Laevolac at ambient temperature, preferably below 25 °C, in its original container. Protect the liquid from moisture and direct sunlight. Do not freeze; keep the bottle tightly closed to maintain stability.

Laevolac is taken orally as a liquid solution. The prescribed volume is measured with a calibrated dosing device and ingested directly or mixed with a small amount of water or juice, according to the healthcare provider’s instructions.

Serious risks include severe electrolyte imbalance, dehydration, and rare allergic reactions such as rash or itching. Patients should be monitored for signs of these events, especially if high doses are used or if they have underlying renal or cardiac conditions.

Laevolac should be avoided in individuals with complete bowel obstruction, known hypersensitivity to lactulose, or in those where rapid fluid loss could be hazardous without close medical supervision.